Holen Sie sich die Stockscreener-App
1.49
22.16%
-0.45
Schlusskurs vom Vortag:
$1.94
Offen:
$1.75
24-Stunden-Volumen:
567.75K
Relative Volume:
2.91
Marktkapitalisierung:
$100.04M
Einnahmen:
$697.00K
Nettoeinkommen (Verlust:
$-39.78M
KGV:
-0.8922
EPS:
-1.67
Netto-Cashflow:
$-8.90M
1W Leistung:
-26.70%
1M Leistung:
+5.59%
6M Leistung:
-11.70%
1J Leistung:
+5.59%
1-Tages-Spanne:
$1.41
$1.79
1-Wochen-Bereich:
$1.41
$2.36
52-Wochen-Spanne:
$1.28
$3.19
Rafael Holdings Inc Stock (RFL) Company Profile
Firmenname
Rafael Holdings Inc
Sektor
Branche
Telefon
212-658-1450
Adresse
520 BROAD STREET, NEWARK
Vergleichen Sie RFL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RFL
Rafael Holdings Inc
|
1.5053 | 100.04M | 697.00K | -39.78M | -8.90M | -1.67 |
|
CBRE
Cbre Group Inc
|
133.84 | 39.60B | 36.74B | 1.01B | 1.35B | 3.27 |
|
CSGP
Costar Group Inc
|
79.96 | 34.20B | 2.81B | 117.20M | -30.60M | 0.29 |
|
BEKE
Ke Holdings Inc Adr
|
18.19 | 22.71B | 12.30B | 566.18M | 1.32B | 0.4805 |
|
JLL
Jones Lang Lasalle Inc
|
237.96 | 11.28B | 24.05B | 536.00M | 508.40M | 11.06 |
|
FSV
Firstservice Corp
|
178.27 | 8.17B | 4.93B | 108.16M | 203.45M | 2.40 |
Rafael Holdings Inc Aktie (RFL) Neueste Nachrichten
Rafael to continue phase 3 study of NPC treatment after DMC review - Investing.com Nigeria
Rafael Holdings Advances Phase 3 Study for NPC1 Treatment - TipRanks
Major Breakthrough: Phase 3 Trial for Fatal Rare Disease NPC1 Gets Critical DMC Approval to Continue - Stock Titan
Rafael Holdings, Inc. (NYSE:RFL) Short Interest Update - MarketBeat
Howard S. Jonas Acquires 13,080,457 Shares of Rafael Holdings, Inc. (NYSE:RFL) Stock - MarketBeat
Rafael Holdings Up 29%, Insider Buyers Are Up 61% - Yahoo Finance
Retail investors invested in Rafael Holdings, Inc. (NYSE:RFL) up 29% last week, insiders too were rewarded - simplywall.st
Rafael Holdings Reports Improved Financial Results and Strategic Progress - TipRanks
Rafael Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2025 - marketscreener.com
Rafael Holdings, Inc. SEC 10-Q Report - TradingView
Rafael (NYSE:RFL) Posts Quarterly Earnings Results - MarketBeat
Rafael Holdings Reports Third Quarter Fiscal 2025 Financial Results - The Manila Times
Rafael Holdings Slashes Losses 85% as Crucial Phase 3 Rare Disease Trial Results Loom - Stock Titan
Rafael Holdings stock surges after CEO acquires $16.7m in shares - Investing.com Nigeria
Rafael Holdings stock surges after CEO acquires $16.7m in shares By Investing.com - Investing.com South Africa
Rafael Holdings Completes $25M Rights Offering - TipRanks
Rafael Holdings, Inc. Announces Final Results and Closing of Rights Offering - The Manila Times
RadNet, Inc. Acquires See-Mode Technologies for Innovation in AI-Powered Ultrasound Diagnostics - The Manila Times
Rafael Holdings Announces Final Results And Closing Of Rights Offering - marketscreener.com
Rafael CEO Backs $25M Rights Offering to Fund Critical Phase 3 Rare Disease Drug Trial - Stock Titan
Israel Defense Exports Hit Record in 2024 as Europe Demand Jumps - Bloomberg
Protara Therapeutics Announces Appointment of William Conkling as Chief Commercial Officer - The Manila Times
Rafael (NYSE:RFL) Trading Up 2.6% – Still a Buy? - Defense World
Protara Therapeutics names new Chief Commercial Officer By Investing.com - Investing.com India
Cancer Drug Veteran Behind Trodelvy Launch Joins Protara as Commercial Chief to Lead Market Strategy - Stock Titan
RFL stock touches 52-week low at $1.28 amid market challenges - Investing.com Australia
Rafael Holdings, Inc. Provides Update to the Description of Subscription Rights Related to its Public Warrants in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trap - The Manila Times
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody - The Manila Times
Rafael Holdings Rights Offering: $25M Deal Terms Revealed, May 29 Deadline Approaches - Stock Titan
Ekso Bionics reports Q1 results, plans reverse stock split - The North Bay Business Journal
Ekso Bionics Accepted into NVIDIA Connect Program - Quantisnow
Dassault Aviation Shares Continue to Drop After the Rafale Jet Shot Down - TECHi
Rafael : to Present at LD Micro Investor Conference - marketscreener.com
Rafael Holdings Enters Standby Purchase Agreement with Chairman - TipRanks
SEC Form 424B3 filed by Rafael Holdings Inc. - Quantisnow
Ekso Bionics: Q1 Earnings Snapshot - CTPost
Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results - ADVFN
Rafael announces revised subscription rights in connection with offering - TipRanks
Rafael Holdings, Inc. Announces Revised Subscription Rights in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™ - The Manila Times
Rafael Holdings, Inc. Announces Revised Subscription Rights in Connection With its Previously ... - Bluefield Daily Telegraph
Rafael Holdings Launches $25M Rights Offering: Key Dates and Terms Investors Must Know - Stock Titan
Oculis Holding AG (NASDAQ:OCS) Shares Bought by Geode Capital Management LLC - Defense World
Upcoming Stock Splits This Week (May 5 to May 9) – Stay Invested - TipRanks
Press Release Distribution & PR Platform - ACCESS Newswire
LD Micro 360 Companies: --Set to Present this Week. - ACCESS Newswire
Metric Deep Dive: Understanding Rafael Holdings Inc (RFL) Through its Ratios - DWinneX
Tronox Holdings plc: Navigating Market Fluctuations with a 857.28M Market Cap - investchronicle.com
Rafael Holdings Inc (RFL) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
Rafael Holdings, Inc. Announces Proposed Terms of a $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™ - The Manila Times
Sonoco Reports First Quarter 2025 Results - The Manila Times
Rafael Holdings Secures Future: $25M Rights Offering Powers Critical Phase 3 Drug Launch Plans - Stock Titan
Finanzdaten der Rafael Holdings Inc-Aktie (RFL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.68%
0.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):